Arbutus announces changes to board of directors and appointment of lindsay androski as ceo

Warminster, pa., feb. 25, 2025 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus) (“arbutus” or the “company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced changes to its board of directors and the appointment of lindsay androski, j.d.

ABUS Ratings Summary

ABUS Quant Ranking